UB Paderborn / Katalog / Suche / in CDI

Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE)

The Journal of dermatological treatment, 2021-11, Vol.32 (8), p.883-893

2021

Volltextzugriff (PDF)

Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States

The Journal of dermatological treatment, 2019-07, Vol.30 (5), p.454-460

2019

Volltextzugriff (PDF)

The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment

The Journal of dermatological treatment, 2019-07, Vol.30 (5), p.446-453

2019

Volltextzugriff (PDF)

Role and pharmacologic significance of cytochrome P‐450 2D6 in oxidative metabolism of toremifene and tamoxifen

International journal of cancer, 2013-03, Vol.132 (6), p.1475-1485

2013

Volltextzugriff (PDF)

PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis

Journal of the American Academy of Dermatology, 2020-07, Vol.83 (1), p.131-138

2020

Volltextzugriff (PDF)

Pharmacodynamics of selective androgen receptor modulators

The Journal of pharmacology and experimental therapeutics, 2003-03, Vol.304 (3), p.1334

2003

Volltextzugriff (PDF)

Targeting type 2 immune activation beyond atopic dermatitis

Annals of allergy, asthma, & immunology, 2024-02, Vol.132 (2), p.121-123

2024

Volltextzugriff (PDF)

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Journal of the American Academy of Dermatology, 2024-03, Vol.90 (3), p.504-511

2024

Volltextzugriff (PDF)

Estrogen Receptor-β-selective Ligands Alleviate High-fat Diet- and Ovariectomy-induced Obesity in Mice

The Journal of biological chemistry, 2010-10, Vol.285 (41), p.31292-31303

2010

Volltextzugriff (PDF)

Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis

Journal of drugs in dermatology, 2018-08, Vol.17 (8), p.880

2018

Volltextzugriff (PDF)

Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis

Journal of drugs in dermatology, 2020-02, Vol.19 (2), p.121

2020

Volltextzugriff (PDF)

Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis

Journal of medical economics, 2020-06, Vol.23 (6), p.641-649

2020

Volltextzugriff (PDF)

Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats

Xenobiotica, 2013-11, Vol.43 (11), p.993-1009

2013

Volltextzugriff (PDF)

Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641-649

Journal of medical economics, 2020-12, Vol.23 (12), p.1501-1502

2020

Volltextzugriff (PDF)

Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study

The Journal of clinical and aesthetic dermatology, 2020-05, Vol.13 (5), p.12-18

2020

Volltextzugriff (PDF)

Toremifene - a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy

Expert opinion on investigational drugs, 2006-03, Vol.15 (3), p.293-305

2006

Volltextzugriff (PDF)

1448 ORAL ADMINISTRATION OF GTX-758, A SELECTIVE ERα AGONIST, INDUCES CHEMICAL CASTRATION BUT NOT GYNECOMASTIA IN MALE MONKEYS

The Journal of urology, 2011-04, Vol.185 (4), p.e581-e581

2011

Volltextzugriff (PDF)

Preclinical Characterization of a Novel Diphenyl Benzamide Selective ERα Agonist for Hormone Therapy in Prostate Cancer

Endocrinology (Philadelphia), 2012-03, Vol.153 (3), p.1070-1081

2012

Volltextzugriff (PDF)

Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms

Xenobiotica, 2011-10, Vol.41 (10), p.851-862

2011

Volltextzugriff (PDF)

Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways

Cancer research (Chicago, Ill.), 2003-01, Vol.63 (2), p.364-374

2003

Volltextzugriff (PDF)

16127 Efficacy of ingenol mebutate in patients with actinic keratosis on face and scalp: Subgroup analysis of a 12-month observational follow-up study according to age (<65 and ≥65 years)

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB172-AB172

2020

Volltextzugriff (PDF)

16258 Evaluation of different approaches in managing local skin reactions with the use of ingenol mebutate 0.015% and 0.05% during the treatment of actinic keratosis

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB58-AB58

2020

Volltextzugriff (PDF)

17754 Treatment success in mild psoriasis patients with fixed-combination calcipotriene and betamethasone dipropionate foam: Results from the PSO-FAST trial

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB198-AB198

2020

Volltextzugriff (PDF)

16419 Real world studies for local skin reactions with the use of ingenol mebutate 0.015% and 0.05% to predict treatment efficacy

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB63-AB63

2020

Volltextzugriff (PDF)

Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis

Skin (Milwood, N.Y.), 2020-09, Vol.4 (5), p.s65

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE)

Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States

The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment

Role and pharmacologic significance of cytochrome P‐450 2D6 in oxidative metabolism of toremifene and tamoxifen

PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis

Pharmacodynamics of selective androgen receptor modulators

Targeting type 2 immune activation beyond atopic dermatitis

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Estrogen Receptor-β-selective Ligands Alleviate High-fat Diet- and Ovariectomy-induced Obesity in Mice

Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis

Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis

Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis

Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats

Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study

Toremifene - a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy

1448 ORAL ADMINISTRATION OF GTX-758, A SELECTIVE ERα AGONIST, INDUCES CHEMICAL CASTRATION BUT NOT GYNECOMASTIA IN MALE MONKEYS

Preclinical Characterization of a Novel Diphenyl Benzamide Selective ERα Agonist for Hormone Therapy in Prostate Cancer

Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms

Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways

16127 Efficacy of ingenol mebutate in patients with actinic keratosis on face and scalp: Subgroup analysis of a 12-month observational follow-up study according to age (<65 and ≥65 years)

16258 Evaluation of different approaches in managing local skin reactions with the use of ingenol mebutate 0.015% and 0.05% during the treatment of actinic keratosis

17754 Treatment success in mild psoriasis patients with fixed-combination calcipotriene and betamethasone dipropionate foam: Results from the PSO-FAST trial

16419 Real world studies for local skin reactions with the use of ingenol mebutate 0.015% and 0.05% to predict treatment efficacy

Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis

Suchergebnisse filtern